{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:35:44Z","timestamp":1793172944417,"version":"4.5.0"},"reference-count":90,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:p>Uveitis associated with demyelinating diseases, particularly multiple sclerosis (MS), has gained increasing attention in recent years. Advances in diagnostic modalities, such as the widespread use of brain magnetic resonance imaging, have facilitated deeper investigation into the pathophysiology of uveitis and revealed stronger associations with MS. Additionally, recent genome-wide association studies and progress in immunology have further expanded our understanding of the complex relationship between these conditions. Of particular interest is the emerging recognition of drug-induced MS, especially linked to tumor necrosis factor-alpha (TNF-\u03b1) inhibitors. While TNF-\u03b1 inhibitors are commonly employed in the treatment of uveitis, accumulating evidence suggests they may carry risks of inducing or exacerbating central nervous system demyelination. This evolving landscape necessitates a careful review of current literature to identify new associations, evaluate the strength of existing evidence, and guide clinical decision-making. Special focus is needed on the optimal use of biological therapies and management strategies for refractory uveitis in the context of MS when conventional treatments fail. This narrative review aims to synthesize recent findings, highlight emerging challenges, and provide practical insights for clinicians managing this complex interplay between uveitis and demyelinating diseases.<\/jats:p>","DOI":"10.4103\/ijo.ijo_3267_25","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T07:00:12Z","timestamp":1787554812000},"page":"1584-1591","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Current perspectives on demyelination and associated uveitis: From pathogenesis to biological therapies"],"prefix":"10.4103","volume":"74","author":[{"given":"Aniruddha","family":"Agarwal","sequence":"first","affiliation":[{"name":"Eye Department, Integrated Surgical Institute (ISI), Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates (UAE)"},{"name":"Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asia","family":"Mubashir","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA"},{"name":"Department of Rheumatology, Integrated Health Services Institute (IHI), Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivam O","family":"Mittal","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA"},{"name":"Neurological Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"R1-20261028","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.semarthrit.2019.06.004","article-title":"New observations and emerging ideas in diagnosis and management of non-infectious uveitis: A review","volume":"49","author":"Rosenbaum","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"R2-20261028","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.autrev.2014.01.006","article-title":"Diagnosis and classification of autoimmune uveitis","volume":"13","author":"Selmi","year":"2014","journal-title":"Autoimmun Rev"},{"key":"R3-20261028","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","article-title":"Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals of Care for UveitiS (FOCUS) initiative","volume":"125","author":"Dick","year":"2018","journal-title":"Ophthalmology"},{"key":"R4-20261028","first-page":"e39965","article-title":"Noninfectious uveitis in rheumatology: Patterns, treatment, and outcomes","volume":"15","author":"Younus","year":"2023","journal-title":"Cureus"},{"issue":"suppl 1","key":"R5-20261028","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1080\/09273948.2016.1255761","article-title":"Epidemiology of uveitis in a tertiary-care referral institute in North India","volume":"25","author":"Dogra","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"R6-20261028","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41433-018-0224-y","article-title":"Infectious uveitis: An Asian perspective","volume":"33","author":"Agarwal","year":"2019","journal-title":"Eye (Lond)"},{"key":"R7-20261028","doi-asserted-by":"crossref","first-page":"94","DOI":"10.18053\/jctres.201502.003","article-title":"Diagnosis and treatment of uveitis; not restricted to the ophthalmologist","volume":"1","author":"van Laar","year":"2015","journal-title":"J Clin Transl Res"},{"key":"R8-20261028","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.pop.2015.05.003","article-title":"Uveitis","volume":"42","author":"Dunn","year":"2015","journal-title":"Prim Care"},{"key":"R9-20261028","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/pn-2024-004451","article-title":"Uveitis for neurologists","volume":"25","author":"Patel","year":"2025","journal-title":"Pract Neurol"},{"key":"R10-20261028","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.survophthal.2024.11.002","article-title":"Uveitis among people with multiple sclerosis: A systematic review and meta-analysis","volume":"70","author":"Vaheb","year":"2025","journal-title":"Surv Ophthalmol"},{"key":"R11-20261028","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000429637","article-title":"Intermediate uveitis and multiple sclerosis: Considerations and necessary consequences for treatment","volume":"23","author":"Kraus-Mackiw","year":"1992","journal-title":"Dev Ophthalmol"},{"key":"R12-20261028","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.survophthal.2016.07.002","article-title":"The association between multiple sclerosis and uveitis","volume":"62","author":"Olsen","year":"2017","journal-title":"Surv Ophthalmol"},{"key":"R13-20261028","doi-asserted-by":"crossref","first-page":"e0307455","DOI":"10.1371\/journal.pone.0307455","article-title":"Uveitis characteristics and multiple sclerosis phenotype of patients with multiple sclerosis-associated uveitis: A systematic review and meta-analysis","volume":"19","author":"Saboya-Galindo","year":"2024","journal-title":"PLoS One"},{"key":"R14-20261028","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/aos.14697","article-title":"Insights into multiple sclerosis-associated uveitis: A scoping review","volume":"99","author":"Casselman","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"R15-20261028","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1080\/09273948.2024.2337839","article-title":"Epidemiological, clinical, and therapeutic profile of uveitis in multiple sclerosis: A multicenter study","volume":"32","author":"Fitoussi","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"R16-20261028","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/09273948.2025.2491567","article-title":"Comprehensive update on multiple sclerosis-associated uveitis and new epidemiological insights from the United Kingdom","volume":"33","author":"Heppell","year":"2025","journal-title":"Ocul Immunol Inflamm"},{"key":"R17-20261028","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1080\/09273948.2025.2495826","article-title":"Long-term effects of adalimumab in juvenile idiopathic arthritis-associated uveitis: 3- and 6-year results of the ADJUVITE trial","volume":"33","author":"Chung","year":"2025","journal-title":"Ocul Immunol Inflamm"},{"key":"R18-20261028","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/art.20904","article-title":"A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis","volume":"53","author":"Smith","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R19-20261028","doi-asserted-by":"crossref","first-page":"e3863","DOI":"10.1097\/MD.0000000000003863","article-title":"Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study","volume":"95","author":"Hibi","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R20-20261028","doi-asserted-by":"crossref","first-page":"e1002901","DOI":"10.1371\/journal.pmed.1002901","article-title":"Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial","volume":"16","author":"Ruscitti","year":"2019","journal-title":"PLoS Med"},{"key":"R21-20261028","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1745-6215-15-14","article-title":"A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)","volume":"15","author":"Ramanan","year":"2014","journal-title":"Trials"},{"key":"R22-20261028","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/mrcr\/rxae069","article-title":"Adalimumab-induced CNS demyelination in a patient with multiple pre-existing autoimmune diseases: Treatment contemplation","volume":"9","author":"Khosravi","year":"2025","journal-title":"Mod Rheumatol Case Rep"},{"key":"R23-20261028","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2018.10.013","article-title":"Uveitis in patients with multiple sclerosis in clinical trials of fingolimod: Incidence, prevalence, and impact on disease course","volume":"126","author":"Lim","year":"2019","journal-title":"Ophthalmology"},{"key":"R24-20261028","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12348-020-00215-1","article-title":"Incidence of uveitis and macular edema among patients taking fingolimod 0.5 mg for multiple sclerosis","volume":"10","author":"Sonne","year":"2020","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"R25-20261028","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1212\/WNL.52.1.179","article-title":"Multiple sclerosis associated with uveitis in two large clinic-based series","volume":"52","author":"Biousse","year":"1999","journal-title":"Neurology"},{"key":"R26-20261028","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/0002-9394(66)91340-7","article-title":"The incidence of uveitis in multiple sclerosis","volume":"62","author":"Bregerbc","year":"1966","journal-title":"Am J Ophthalmol"},{"key":"R27-20261028","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1352458514539782","article-title":"Uveitis as a prognostic factor in multiple sclerosis","volume":"21","author":"Shugaiv","year":"2015","journal-title":"Mult Scler"},{"key":"R28-20261028","first-page":"203","article-title":"The appearance of pars planitis in multiple sclerosis","volume":"29","author":"Vidovi\u0107","year":"2005","journal-title":"Coll Antropol"},{"key":"R29-20261028","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1177\/1352458510369146","article-title":"Autoimmune diseases prior to the diagnosis of multiple sclerosis: A population-based case-control study","volume":"16","author":"Langer-Gould","year":"2010","journal-title":"Mult Scler"},{"key":"R30-20261028","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1080\/09273948.2016.1249376","article-title":"Ocular autoimmune systemic inflammatory infectious study (OASIS) - Report 1: Epidemiology and classification","volume":"26","author":"Chen","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"R31-20261028","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/bjo.73.9.714","article-title":"A point prevalence study of 150 patients with idiopathic retinal vasculitis: 1. Diagnostic value of ophthalmological features","volume":"73","author":"Graham","year":"1989","journal-title":"Br J Ophthalmol"},{"key":"R32-20261028","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/09273940490895344","article-title":"Multiple sclerosis-associated uveitis","volume":"12","author":"Zein","year":"2004","journal-title":"Ocul Immunol Inflamm"},{"key":"R33-20261028","doi-asserted-by":"crossref","first-page":"8734","DOI":"10.12659\/MSM.910749","article-title":"A retrospective observational study of uveitis in a single center in Poland with a review of findings in Europe","volume":"24","author":"Brydak-Godowska","year":"2018","journal-title":"Med Sci Monit"},{"key":"R34-20261028","first-page":"1010","article-title":"Uveitis associated with multiple sclerosis: Complications and visual prognosis","volume":"7","author":"Kaya","year":"2014","journal-title":"Int J Ophthalmol"},{"key":"R35-20261028","doi-asserted-by":"crossref","first-page":"e909","DOI":"10.1212\/NXI.0000000000000909","article-title":"Intermediate uveitis associated with MS","volume":"8","author":"Abraham","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R36-20261028","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1136\/bjophthalmol-2015-307269","article-title":"Intermediate uveitis and multiple sclerosis: To scan or not to scan","volume":"99","author":"Petrushkin","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R37-20261028","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12348-023-00337-2","article-title":"Bilateral exudative retinal detachment, unusual pattern of uveitis with multiple sclerosis","volume":"13","author":"Helal","year":"2023","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"R38-20261028","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1080\/09273948.2022.2103717","article-title":"Occlusive retinal vasculitis in patients with multiple sclerosis","volume":"31","author":"Saifaldein","year":"2023","journal-title":"Ocul Immunol Inflamm"},{"key":"R39-20261028","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3109\/09273948.2011.602500","article-title":"Bilateral rubeosis iridis and rubeotic glaucoma due to peripheral occlusive vasculitis associated with multiple sclerosis","volume":"19","author":"Turner","year":"2011","journal-title":"Ocul Immunol Inflamm"},{"key":"R40-20261028","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s00415-019-09288-y","article-title":"Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing-remitting multiple sclerosis","volume":"266","author":"Gao","year":"2019","journal-title":"J Neurol"},{"key":"R41-20261028","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jfo.2010.11.001","article-title":"[Multiple evanescent white dot syndrome and multiple sclerosis]","volume":"34","author":"Querques","year":"2011","journal-title":"J Fr Ophtalmol"},{"key":"R42-20261028","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ajo.2021.03.044","article-title":"Classification criteria for multiple sclerosis-associated intermediate uveitis","volume":"228","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"R43-20261028","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s12035-024-04264-8","article-title":"Genetic contribution to medium-term disease activity in multiple sclerosis","volume":"62","author":"Mascia","year":"2025","journal-title":"Mol Neurobiol"},{"key":"R44-20261028","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00129785-200202010-00004","article-title":"Genetics of multiple sclerosis: Linkage and association studies","volume":"2","author":"Giordano","year":"2002","journal-title":"Am J Pharmacogenomics"},{"key":"R45-20261028","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0161-6420(99)90122-7","article-title":"Pars planitis: Clinical features and class II HLA associations","volume":"106","author":"Raja","year":"1999","journal-title":"Ophthalmology"},{"key":"R46-20261028","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1080\/09273948.2024.2316759","article-title":"Ophthalmological and neurological findings in patients with idiopathic uveitis associated with retinal vasculitis and the relation with the HLA DR15 allele","volume":"32","author":"De Man","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"R47-20261028","doi-asserted-by":"crossref","first-page":"1514080","DOI":"10.3389\/fimmu.2025.1514080","article-title":"IL-6\/IL-12 superfamily of cytokines and regulatory lymphocytes play critical roles in the etiology and suppression of CNS autoimmune diseases","volume":"16","author":"Yadav","year":"2025","journal-title":"Front Immunol"},{"key":"R48-20261028","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3390\/genes16111311","article-title":"Exome sequencing uncovers genetic drivers of multiple sclerosis in a multiplex family","volume":"16","author":"Lintas","year":"2025","journal-title":"Genes (Basel)"},{"key":"R49-20261028","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12035-025-05436-w","article-title":"Exome sequencing and molecular modeling reveal novel loci in familial multiple sclerosis: The importance of BTNL3 and BTNL8 in disease pathogenesis","volume":"63","author":"Torabi-Rahvar","year":"2025","journal-title":"Mol Neurobiol"},{"key":"R50-20261028","doi-asserted-by":"crossref","first-page":"1656422","DOI":"10.3389\/fimmu.2025.1656422","article-title":"The critical role of Th17 cells and IL-17A in autoimmune and inflammation-associated neurological diseases: mechanisms and therapeutic perspectives","volume":"16","author":"Xu","year":"2025","journal-title":"Front Immunol"},{"key":"R51-20261028","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.4049\/jimmunol.174.4.2327","article-title":"Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction","volume":"174","author":"Harry","year":"2005","journal-title":"J Immunol"},{"key":"R52-20261028","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/09273948.2023.2236211","article-title":"Uveitis in the setting of co-existing systemic sarcoidosis and multiple sclerosis","volume":"32","author":"Gnanaraj","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"R53-20261028","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/WNO.0b013e3180325d84","article-title":"Vogt-Koyanagi-Harada syndrome in a case of multiple sclerosis","volume":"27","author":"Montero","year":"2007","journal-title":"J Neuroophthalmol"},{"key":"R54-20261028","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1352458514564491","article-title":"A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult Scler"},{"key":"R55-20261028","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40264-017-0551-0","article-title":"Occurrence of multiple sclerosis after drug exposure: Insights from evidence mapping","volume":"40","author":"Antonazzo","year":"2017","journal-title":"Drug Saf"},{"key":"R56-20261028","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1080\/14740338.2018.1506763","article-title":"Multiple sclerosis as an adverse drug reaction: Clues from the FDA adverse event reporting system","volume":"17","author":"Antonazzo","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"R57-20261028","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s11033-025-10572-6","article-title":"Mapping the complexity of multiple sclerosis: A novel perspective on genetic, environmental, and neurobiological insights","volume":"52","author":"Omidi","year":"2025","journal-title":"Mol Biol Rep"},{"key":"R58-20261028","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/pds.4357","article-title":"Drug exposure and the risk of multiple sclerosis: A systematic review","volume":"27","author":"Yong","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R59-20261028","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/jnnp-2024-334062","article-title":"Vitamin D affects the risk of disease activity in multiple sclerosis","volume":"96","author":"Giordano","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R60-20261028","doi-asserted-by":"crossref","first-page":"123161","DOI":"10.1016\/j.jns.2024.123161","article-title":"Environmental factors related to multiple sclerosis progression","volume":"464","author":"Gouider","year":"2024","journal-title":"J Neurol Sci"},{"key":"R61-20261028","doi-asserted-by":"crossref","first-page":"1706133","DOI":"10.3389\/fmicb.2025.1706133","article-title":"Double-stranded RNA antiviral signature in early multiple sclerosis","volume":"16","author":"Gouzouasis","year":"2025","journal-title":"Front Microbiol"},{"key":"R62-20261028","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1080\/09273948.2022.2113800","article-title":"Multiple sclerosis in a patient with intermediate uveitis and juvenile idiopathic arthritis treated with adalimumab: A case report","volume":"31","author":"Rojas-Carabali","year":"2023","journal-title":"Ocul Immunol Inflamm"},{"key":"R63-20261028","first-page":"e558","article-title":"Risk of multiple sclerosis among users of antitumor necrosis factor \u03b1 in 4 Canadian provinces: A population-based study","volume":"100","author":"Li","year":"2023","journal-title":"Neurology"},{"key":"R64-20261028","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.3390\/biomedicines10082041","article-title":"Juvenile idiopathic arthritis, uveitis and multiple sclerosis: Description of two patients and literature review","volume":"10","author":"Chighizola","year":"2022","journal-title":"Biomedicines"},{"key":"R65-20261028","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s00296-021-04995-0","article-title":"Demyelinating disease (multiple sclerosis) in a patient with psoriatic arthritis treated with adalimumab: A case-based review","volume":"41","author":"Bare\u0161i\u0107","year":"2021","journal-title":"Rheumatol Int"},{"key":"R66-20261028","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamaneurol.2020.1162","article-title":"Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol"},{"key":"R67-20261028","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/epirev\/mxac001","article-title":"The conundrum of clinical trials for the uveitides: Appropriate outcome measures for one treatment used in several diseases","volume":"44","author":"Jabs","year":"2022","journal-title":"Epidemiol Rev"},{"key":"R68-20261028","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","article-title":"Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III","volume":"125","author":"Suhler","year":"2018","journal-title":"Ophthalmology"},{"key":"R69-20261028","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1007\/s10067-018-4133-z","article-title":"Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies","volume":"37","author":"Fabiani","year":"2018","journal-title":"Clin Rheumatol"},{"key":"R70-20261028","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1089\/jop.2011.0199","article-title":"Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis","volume":"28","author":"Farvardin","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"key":"R71-20261028","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1001\/jamaneurol.2024.3524","article-title":"Risk of inflammatory central nervous system diseases after tumor necrosis factor-inhibitor treatment for autoimmune diseases: A systematic review and meta-analysis","volume":"81","author":"Xie","year":"2024","journal-title":"JAMA Neurol"},{"key":"R72-20261028","doi-asserted-by":"crossref","first-page":"e46040","DOI":"10.1097\/MD.0000000000046040","article-title":"Global burden of TNF-\u03b1 inhibitors associated demyelinating diseases: A global disproportionality analysis","volume":"104","author":"Kim","year":"2025","journal-title":"Medicine (Baltimore)"},{"issue":"Suppl 1","key":"R73-20261028","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1177\/1352458519950101032","article-title":"Interferon alpha treatment of relapsing-remitting multiple sclerosis: Long-term study of the correlations between clinical and magnetic resonance imaging results and effects on the immune function","volume":"1","author":"Durelli","year":"1995","journal-title":"Mult Scler"},{"key":"R74-20261028","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archneur.55.6.793","article-title":"Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis","volume":"55","author":"van Oosten","year":"1998","journal-title":"Arch Neurol"},{"key":"R75-20261028","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11910-017-0742-1","article-title":"CNS demyelination with TNF-\u03b1 blockers","volume":"17","author":"Kemanetzoglou","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R76-20261028","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.semarthrit.2010.06.004","article-title":"Demyelinating disease in patients treated with TNF antagonists in rheumatology: Data from BIOBADASER, a pharmacovigilance database, and a systematic review","volume":"40","author":"Fern\u00e1ndez-Espartero","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"R77-20261028","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6","article-title":"Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: By what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?","volume":"44","author":"Robinson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R78-20261028","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1080\/09273948.2022.2118134","article-title":"Predictive factors for magnetic resonance imaging changes suggestive of demyelination in adult patients with uveitis scanned prior to commencing adalimumab therapy","volume":"31","author":"Sanghi","year":"2023","journal-title":"Ocul Immunol Inflamm"},{"key":"R79-20261028","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1080\/09273948.2020.1870145","article-title":"Relevance of brain MRI in patients with uveitis: retrospective cohort on 402 patients","volume":"30","author":"Chirpaz","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"R80-20261028","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3899\/jrheum.080102","article-title":"Uveitis subtypes in a german interdisciplinary uveitis center--analysis of 1916 patients","volume":"36","author":"Jakob","year":"2009","journal-title":"J Rheumatol"},{"key":"R81-20261028","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: Recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"R82-20261028","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1080\/09273948.2024.2332783","article-title":"Multiple sclerosis-associated uveitis: A case report of refractory bilateral chronic granulomatous panuveitis successfully treated with tocilizumab","volume":"32","author":"Gil","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"R83-20261028","doi-asserted-by":"crossref","first-page":"102152","DOI":"10.1016\/j.msard.2020.102152","article-title":"Effectiveness and safety profile of anakinra in a HLA-B27 positive patient with multiple sclerosis-associated uveitis","volume":"42","author":"Lopalco","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"R84-20261028","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.oftal.2016.11.018","article-title":"Efficacy of immunomodulatory therapy with interferon-\u03b2 or glatiramer acetate on multiple sclerosis-associated uveitis","volume":"92","author":"Velazquez-Villoria","year":"2017","journal-title":"Arch Soc Esp Oftalmol"},{"key":"R85-20261028","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s10792-016-0370-9","article-title":"Alemtuzumab-induced remission of multiple sclerosis-associated uveitis","volume":"37","author":"Willis","year":"2017","journal-title":"Int Ophthalmol"},{"key":"R86-20261028","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/09273948.2021.1980809","article-title":"Case Report: Recurrent severe uveitis secondary to primary progressive multiple sclerosis responsive to ocrelizumab","volume":"31","author":"Guo","year":"2023","journal-title":"Ocul Immunol Inflamm"},{"key":"R87-20261028","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1111\/ene.15453","article-title":"Anti-CD20 therapy for multiple sclerosis-associated uveitis: A case series","volume":"29","author":"Stascheit","year":"2022","journal-title":"Eur J Neurol"},{"key":"R88-20261028","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4103\/IJO.IJO_1724_23","article-title":"Multiple sclerosis-associated uveitis - A series from South India","volume":"72","author":"Babu","year":"2024","journal-title":"Indian J Ophthalmol"},{"key":"R89-20261028","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12348-025-00522-5","article-title":"Safety and efficacy of rituximab in refractory noninfectious uveitis and scleritis","volume":"15","author":"Al Ghulaiga","year":"2025","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"R90-20261028","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12348-024-00405-1","article-title":"A case report of pediatric-onset MS associated uveitis","volume":"14","author":"Mahdizad","year":"2024","journal-title":"J Ophthalmic Inflamm Infect"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3267_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:00:24Z","timestamp":1793170824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3267_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":90,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_3267_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"2025-12-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}